|
Re: Resverlogix Reaches Agreement With FDA for Key Aspects of Apabetalone Registration Enabling Study
|
3
|
Resverlogix Corp.
|
Jun 23, 2020 02:26AM
|
|
Re: Resverlogix Receives Approval From Health Canada To Proceed With Fabry Disease Clinical Trial With Lead Compound Apabetalone
|
4
|
Resverlogix Corp.
|
May 30, 2017 12:47PM
|
|
Re: Resverlogix Receives FDA Protocol Acceptance for the Ongoing Phase 3 BETonMACE Trial
|
6
|
Resverlogix Corp.
|
Jan 11, 2018 01:23PM
|
|
Re: Resverlogix Receives FDA Protocol Acceptance for the Ongoing Phase 3 BETonMACE Trial
|
2
|
Resverlogix Corp.
|
Jan 11, 2018 04:39PM
|
|
Re: Resverlogix Repays $68.8 Million Loan
|
2
|
Resverlogix Corp.
|
Dec 07, 2017 02:16AM
|
|
Re: Resverlogix Repays $68.8 Million Loan
|
3
|
Resverlogix Corp.
|
Dec 07, 2017 10:35AM
|
|
Re: Resverlogix Repays $68.8 Million Loan
|
3
|
Resverlogix Corp.
|
Dec 07, 2017 12:17PM
|
|
Re: Resverlogix Repays $68.8 Million Loan
|
2
|
Resverlogix Corp.
|
Dec 07, 2017 01:02PM
|
|
Re: Resverlogix Repays $68.8 Million Loan
|
1
|
Resverlogix Corp.
|
Dec 07, 2017 08:12PM
|
|
Re: Resverlogix Reports Filing of New Intellectual Property on Key Renal Protection and Glucose Control Markers
|
2
|
Resverlogix Corp.
|
Nov 02, 2020 10:59PM
|
|
Re: Resverlogix Reports Filing of New Intellectual Property on Key Renal Protection and Glucose Control Markers
|
5
|
Resverlogix Corp.
|
Nov 02, 2020 12:50PM
|
|
Re: Resverlogix Reports Filing of New Intellectual Property on Key Renal Protection and Glucose Control Markers
|
6
|
Resverlogix Corp.
|
Nov 02, 2020 01:14PM
|
|
Re: Resverlogix Reports Filing of New Intellectual Property on Key Renal Protection and Glucose Control Markers
|
8
|
Resverlogix Corp.
|
Nov 02, 2020 06:23PM
|
|
Re: Resverlogix Reports Filing of New Intellectual Property on Key Renal Protection and Glucose Control Markers
|
6
|
Resverlogix Corp.
|
Nov 02, 2020 06:41PM
|
|
Re: Resverlogix Reports Filing of New Intellectual Property on Key Renal Protection and Glucose Control Markers
|
5
|
Resverlogix Corp.
|
Nov 02, 2020 07:32PM
|
|
Re: Resverlogix to Present at the Clinical Trials on Alzheimer's Disease Congress 2019
|
5
|
Resverlogix Corp.
|
Dec 02, 2019 11:33AM
|
|
Re: Resverlogix to Present at the Clinical Trials on Alzheimer's Disease Congress 2019
|
1
|
Resverlogix Corp.
|
Dec 02, 2019 12:13PM
|
|
Re: Revamped website
|
5
|
Resverlogix Corp.
|
Jan 06, 2019 09:43PM
|
|
Re: Revenue Canada
|
2
|
Resverlogix Corp.
|
Nov 15, 2019 12:42PM
|
|
Re: Reverse Split Thoughts
|
3
|
Resverlogix Corp.
|
Apr 30, 2023 12:44PM
|
